Biological E Ltd, a Hyderabad-based pharmaceutical business, announced on Monday that its coronavirus vaccine, Corbevax, has acquired emergency use approval in India for children aged 12 to 18.&nbsp;

Corbevax is India's third homegrown vaccine.

The Drug Controller General of India (DCGI), Dr. V. G. Somani, granted the approval for Corbevax.

So far, only children aged 15 and up have been vaccinated in India so far.

More than 76 million children aged 15 to 17 have been vaccinated, mostly with Covaxin, according to government estimates.&nbsp;

According to Dr. NK Arora, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunization (NTAGI), the vaccine is safe and has higher immunogenicity and antibody levels than some other vector vaccines.

In compared to Omicron, the vaccine has showed "greater action," according to the NTAGI chief.

According to sources, the Indian government has made an order with Biological E for five crore doses of the 'Corbevax' COVID-19 vaccine, each costing Rs 145.

Corbevax in late December was given emergency use approval for use in adults, but it has yet to be included in the national immunisation program. 
 
On August 21, last year, the Centre placed an order for 300 million&nbsp;Corbevax medicines.&nbsp; 
 
So far, India's vaccination programme has employed almost 1.76 billion vaccine doses, with roughly 84 per cent of those being a domestic version of AstraZeneca's COVID-19 shot made by the Serum Institute of India.

The third wave of COVID-19 infections in India, caused by the Omicron coronavirus variety, has largely subsided, with the government reporting 16,051 infections on Monday, down from over 300,000 in late January. 
 
(With inputs from agencies)

Biological E Ltd, a Hyderabad-based pharmaceutical business, announced on Monday that its coronavirus vaccine, Corbevax, has acquired emergency use approval in India for children aged 12 to 18.

Biological E Ltd, a Hyderabad-based pharmaceutical business, announced on Monday that its coronavirus vaccine, Corbevax, has acquired emergency use approval in India for children aged 12 to 18. Corbevax is India's third homegrown vaccine. The Drug Controller General of India (DCGI), Dr. V. G. Somani, granted the approval for Corbevax. So far, only children aged 15 and up have been vaccinated in India so far. More than 76 million children aged 15 to 17 have been vaccinated, mostly with Covaxin, according to government estimates. According to Dr. NK Arora, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunization (NTAGI), the vaccine is safe and has higher immunogenicity and antibody levels than some other vector vaccines. In compared to Omicron, the vaccine has showed "greater action," according to the NTAGI chief. According to sources, the Indian government has made an order with Biological E for five crore doses of the 'Corbevax' COVID-19 vaccine, each costing Rs 145. Corbevax in late December was given emergency use approval for use in adults, but it has yet to be included in the national immunisation program. On August 21, last year, the Centre placed an order for 300 million Corbevax medicines. So far, India's vaccination programme has employed almost 1.76 billion vaccine doses, with roughly 84 per cent of those being a domestic version of AstraZeneca's COVID-19 shot made by the Serum Institute of India. The third wave of COVID-19 infections in India, caused by the Omicron coronavirus variety, has largely subsided, with the government reporting 16,051 infections on Monday, down from over 300,000 in late January. (With inputs from agencies)

Biological E's Corbevax gets emergency approval for 12-18 age group

As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, foreign delegates from more than 60 countries on Wednesday arrived in Hyderabad to visit leading biotech companies in India which are developing COVID-19 vaccines.

The envoys first stopped at Hyderabad-based Bharat Biotech and will next visit Biological E. Ltd.

Bharat Biotech, developing India's first indigenous vaccine candidate, Covaxin, with Indian Council of Medical Research. Covaxin is claimed to be at least 60 per cent effective.

Bharat Biotech had started the phase 3 trials earlier in November with 26,000 volunteers across 22 sites in India, making it the largest COVID-19 clinical trial in the country.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Telangana: The 64 foreign envoys seated for briefing, at Bharat Biotech in Hyderabad. They are being briefed by Dr Krishna Ella, Chairman &amp; Managing Director of Bharat Biotech International Limited.<a href="https://twitter.com/hashtag/COVID19?src=hash&amp;ref_src=twsrc%5Etfw">#COVID19</a> <a href="https://t.co/Oq6o7U8N7b">https://t.co/Oq6o7U8N7b</a> <a href="https://t.co/cmot8mGpo0">pic.twitter.com/cmot8mGpo0</a>
— ANI (@ANI) <a href="https://twitter.com/ANI/status/1336569892401627136?ref_src=twsrc%5Etfw">December 9, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The visit of the Foreign Heads of Missions (HoMs) in India was organised in continuation of the COVID-19 briefing by the Ministry of External Affairs (MEA) on November 6.

The first batch of diplomats included envoys from Australia, Denmark, Iran, Bhutan, Brazil, Myanmar, Slovenia, Trinidad &amp; Tobago, South Korea, Afghanistan, Sri Lanka, among others.

(With inputs from agencies)

As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, foreign delegates from more than 60 countries on Wednesday arrived in Hyderabad to visit leading biotech companies in India which are developing COVID-19 vaccines.

As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, foreign delegates from more than 60 countries on Wednesday arrived in Hyderabad to visit leading biotech companies in India which are developing COVID-19 vaccines. The envoys first stopped at Hyderabad-based Bharat Biotech and will next visit Biological E. Ltd. Bharat Biotech, developing India's first indigenous vaccine candidate, Covaxin, with Indian Council of Medical Research. Covaxin is claimed to be at least 60 per cent effective. Bharat Biotech had started the phase 3 trials earlier in November with 26,000 volunteers across 22 sites in India, making it the largest COVID-19 clinical trial in the country. Telangana: The 64 foreign envoys seated for briefing, at Bharat Biotech in Hyderabad. They are being briefed by Dr Krishna Ella, Chairman & Managing Director of Bharat Biotech International Limited.#COVID19 https://t.co/Oq6o7U8N7b pic.twitter.com/cmot8mGpo0 — ANI (@ANI) December 9, 2020 × The visit of the Foreign Heads of Missions (HoMs) in India was organised in continuation of the COVID-19 briefing by the Ministry of External Affairs (MEA) on November 6. The first batch of diplomats included envoys from Australia, Denmark, Iran, Bhutan, Brazil, Myanmar, Slovenia, Trinidad & Tobago, South Korea, Afghanistan, Sri Lanka, among others. (With inputs from agencies)

64 foreign envoys arrive at Bharat Biotech facility in Hyderabad that is developing Covid-19 vaccine

Indian Prime Minister Narendra Modi interacted with various vaccine developers like the Gennova Biopharma and Biological E Ltd and Dr. Reddy's laboratories Ltd. This comes after the PM visited three Biotechnology firms.

News Alert: Indian PM Modi holds virtual meet with 3 biotechnology firms

biological-e-ltd

Biological E Ltd, News on Biological E Ltd, stories on Biological E Ltd, articles on Biological E Ltd, Biological E Ltd stories at Wion, Biological E Ltd news, Biological E Ltd latest news

biological e-ltd

Biological E's Corbevax gets emergency approval for 12-18 age group

64 foreign envoys arrive at Bharat Biotech facility in Hyderabad that is developing Covid-19 vaccine

News Alert: Indian PM Modi holds virtual meet with 3 biotechnology firms